<DOC>
	<DOCNO>NCT00503750</DOCNO>
	<brief_summary>This phase II one arm study . Patients HER2 ( Human Epidermal Growth Factor Receptor 2 ) positive early stage breast cancer receive ABI-007 vinorelbine combination trastuzumab breast surgery .</brief_summary>
	<brief_title>Phase II Neoadjuvant Trial Trastuzumab Combination With Dose-Dense ABI-007 ( Abraxaneâ„¢ )</brief_title>
	<detailed_description>This phase II one arm study . Patients HER2 ( Human Epidermal Growth Factor Receptor 2 ) positive early stage breast cancer receive ABI-007 vinorelbine combination trastuzumab breast surgery . Approximately 50 patient take part multi-sites potentially 20 patient participate Emory Winship Cancer Institute , Grady Memorial Hospital , Emory Crawford Long Hospital Atlanta , Georgia .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast carcinoma . Early stage breast cancer stage I ( tumor size great 1 cm ) , II IIA . 3+ HER2 overexpression IHC 2+ HER2 overexpression FISH positivity . Patients must measurable disease define palpable lesion diameter great equal 1 cm measurable caliper and/or positive mammogram ultrasound least one dimension great equal 1 cm . Bilateral mammogram clip placement require study entry . Baseline measurement indicator lesion must record patient registration form . To valid baseline , measurement must make within 14 day ( 46 week xrays scan ) immediately precede patient 's entry study . ECOG performance status 0 2 within 14 day study entry . Normal ( great 50 % ) leave ventricular ejection fraction ( LVEF ) MUGA scan echocardiography . Must 18 year age old . Women men childbearing potential must use reliable appropriate contraceptive method . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Final eligibility clinical trial determine health professional conduct trial . Evidence disease outside breast chest wall , except ipsilateral axillary lymph node . Prior chemotherapy , hormonal therapy , biologic therapy radiation therapy breast cancer . Patients history DCIS eligible treat surgery alone . Medical , psychological , surgical condition investigator feel might compromise study participation . Pregnant lactate woman eligible . Patients history previous current malignancy site exception adequately treat carcinoma situ cervix basal squamous cell carcinoma skin . Patients history malignancy remain disease free great five year eligible . Evidence sensory and/or peripheral neuropathy . Serious , uncontrolled , concurrent infection . Major surgery within 4 week start study treatment without complete recovery . Final eligibility clinical trial determine health professional conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>